Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadovist vs ProHance for contrast-enhanced MRI of the CNS
2007-004746-33Phase 3Completed
- Sponsor
- Bayer HealthCare
- Start
- Apr 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gadobutrol in diagnostic procedure (2 arms), sponsored by Bayer HealthCare. Primary endpoints: Lesion visualization parameters (combined unenhanced + gadobutrol-enhanced MRI vs unenhanced MRI) and Noninferiority of gadobutrol vs gadoteridol (0.1 mmol/kg) for CNS lesion visualization. Started Apr 2008; status: completed.
02
Drugs
gadobutrol
03
Conditions
diagnostic procedure
Beyond the preview
Go deeper on 2007-004746-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004746-33.